Abstract:Yin Tang, 1, 2, &ast Yu Cui, 3– 5, &ast Lin-lin Li, 6, &ast Ya-ping Guan, 3– 5 Dong-feng Feng, 3– 5 Bei-bei Yin, 3– 5 Xue-feng Liang, 2 Jing Yin, 2 Rui Jiang, 6 Jing Liang, 3– 5 Ya-hong Sun, 2 Jun Wang 3– 5 1 Postgraduate Department, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, People's Republic of China; 2 Department of Oncology, The Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences), Jinan, 250031, People's Republic of China; 3 Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, People's Republic of China; 4 Shandong Lung Cancer Institute, Jinan, 250014, People's Republic of China; 5 Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, 250014, People's Republic of China; 6 Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ya-hong Sun Department of Oncology, The Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences), No. 38, Wu Yingshan Road, Tianqiao District, Jinan, 250031, People's Republic of China Tel +86-531-58628551 Email Jun Wang Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, No. 16766, Jingshi Road, Lixia District, Jinan, 250014, People's Republic of China Tel +86-531-89268839 Email Purpose: To evaluate the dynamics of early serum tumour markers (STMs) and the neutrophil-to-lymphocyte ratio (NLR) to predict clinical efficacy and prognosis of advanced non-small-cell lung cancer (NSCLC) patients who received programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. Patients and Methods: We retrospectively reviewed patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors between September 2017 and August 2020. NLR and STMs were routinely measured between immunotherapy initiation and the first radiological evaluation. A combination score based on the leading STM and NLR and their dynamic changes was established. The effects of leading STM change, NLR change, and the combination score on the objective response rate (ORR), durable clinical benefit (DCB), progression-free survival (PFS), and overall survival (OS) were analysed. The accuracy of the combination score was evaluated by receiver operating characteristic (ROC) curve and the area under the curve (AUC). Results: Overall, 124 patients were included in this retrospective cohort study. The ORR was 22.8%, DCB was 54.5%, and the median OS and PFS were 21.6 and 14.9 months, respectively. Patients with low combination scores had a significantly improved ORR and DCB compared with those with intermediate or high scores ( P = 0.002 for ORR, P < 0.0001 for DCB). In a multivariate model, the combination score was an independent indicator of PFS ( P < 0.0001) and OS ( P < 0.0001). The AUC demonstrated that the combination score (AUC = 0.706) has greater predictive power than either the posttreatment NLR (AUC = 0.668) or the leading STM change (AUC = 0.648) alone. Conclusion: An easy, cost-effective, and novel combination score based on the dynamics of an early STM and the NLR can accurately predict the clinical efficacy of PD-1/PD-L1 inhibitors and prognosis in advanced NSCLC patients. Keywords: serum tumour marker, neutrophil-to-lymphocyte ratio, PD-1 inhibitors, non-small-cell lung cancer, prognosis Lung cancer has the highest mortality rate among all cancers worldwide and in China and accounts for 23% of all cancer-related deaths. Approximately 75% to 80% of all lung cancer cases are non-small-cell lung cancer (NSCLC), which usually presents as advanced or metastatic disease at initial diagnosis. 1–3 Immunotherapy consisting of immune checkpoint inhibitor (ICI) blockade, and specifically programmed cell death-ligand 1 (PD-L1) or programmed cell death-1 (PD-1) inhibitors, has revolutionized therapeutic strategies for advanced human cancers over the last few years. Durable responses and improved survival can be observed in advanced NSCLC patients treated with ICIs as first- or second-line treatments, as can tolerated immune-related adverse events. However, by -Abstract Truncated-

Dynamics of Serum Tumor Markers Predict Benefit from Immune Checkpoint Inhibitors in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Dynamics of Serum Tumor Markers Can Serve As a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Abstract 620: Associations of Genomic Alteration, Tumor Mutational Burden with PD-L1 Expression and Response to Immune Checkpoint Inhibitors in Chinese Lung Patients

Longitudinal High-Dimensional Analysis Identifies Biomarkers of Response to Anti-PD-1 Immunotherapy

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

Predictive Value of the Biomarker of Peripheral Blood of Lung Carcinoma Patients Responding to PD-1 Treatment: A Real-Word Study.

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients

Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China

Prognostic Role of Serum Cytokines Level in Non-Small Cell Lung Cancer Patients with Anti-Pd-1 and Chemotherapy Combined Treatment

Dynamic Changes in Blood PD-L1 Expression Predict the Efficacy and Overall Survival of Immune Checkpoint Inhibitor Treatment in Non-Small-Cell Lung Cancer Patients

Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer

Clinical Evaluation of Serum Tumor Markers in Patients with Advanced-Stage Non-Small Cell Lung Cancer Treated with Palliative Chemotherapy in China

Peripheral CD4 + T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer

A novel combination score based on early serum tumor markers and neutrophil-to-lymphocyte ratio dynamics predicts response to PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer.

The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma

The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma

Plasma Cytokines Interleukin-18 and C-X-C Motif Chemokine Ligand 10 Are Indicative of the Anti-Programmed Cell Death Protein-1 Treatment Response in Lung Cancer Patients

Discovery of Efficacy Biomarkers for Non-Small Cell Lung Cancer with First-Line Anti-Pd-1 Immunotherapy by Data-Independent Acquisition Mass Spectrometry

Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer

[Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors]